Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

International Clinical Psychopharmacology

Volumn 18, Issue 2, 2003, Pages 81-85

  Hartmann, Susanne ^a   Möbius, Hans Jörg ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; Memantine; NMDA antagonist; Vascular dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; RIVASTIGMINE; TACRINE;

ADULT; AGED; AGGRESSIVENESS; ALZHEIMER DISEASE; ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; HEALTH STATUS; HUMAN; IMPULSIVENESS; INCONTINENCE; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PSYCHOSIS; RESTLESSNESS; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARBAMATES; CHOLINESTERASE INHIBITORS; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; INDANS; MEMANTINE; MIDDLE AGED; PHENYLCARBAMATES; PIPERIDINES; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES; TACRINE; TREATMENT OUTCOME;

EID: 0037345885     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200303000-00003     Document Type: Article

References (27)

1. Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G (2000) Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2:85-97.
2. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R (2001) Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 58:417-422.
3. Förstl H, Bickel H, Kurz A (1999) Alzheimer Demenz - Grundlagen, Klinik und Therapie, 1st ed. Heidelberg: Springer-Verlag.
4. Francis PT, Sims NR, Procter AW, Bowen DM (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease - investigative and therapeutic perspectives. J Neurochem 60:263-291.
5. Geula C, Mesulam NM (1994) Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL (editors): Alzheimer disease. New York: Raven Press; pp. 263-291.
6. Hofman A, Rocca WA, Brayne C, Breteler MMB, Clarke M, Cooper B, et al. (1991) The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 20:736-748.
7. Jacobson R (1999) Memantine led to functional improvement and reduced care dependence in severe dementia. Evidence-Based Ment Health 2:112-113.
8. Jorm AF, Jolley D (1998) The incidence of dementia: a meta-analysis. Neurology 51:728-733.
9. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271:985-991.
10. Leon J, Cheng CD, Neumann PJ (1998) Alzheimer's disease care: Costs and potential savings. Healthy Aff Millwood 17:206-216.
11. Li S, Mallory M, Alford M, Tanaka S, Masliah E (1997) Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 56:901-911.
12. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MMB, et al. (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurol 54(suppl 5):S4-S9.
13. Miguel-Hidalgo JJ, Alvarez XA, Quack G, Cacabelos R (2002) Memantine prevents beta-amyloid-induced neurotoxicity and learning impairment in rats. Neurobiol Aging 23:385.
14. Möbius HJ (1999) Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Disease Assoc Disord 13:S172-S178.
15. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. (2001) A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Alzheimer's Disease Education and Referral (ADEAR) Center. Neurology 14:481-488.
16. National Institute on Aging (November 1998) Prevalence and costs of Alzheimer's disease. Progress Report on Alzheimer's Disease. NIH Publication No. 99-3616. Bethesda, Maryland: NIH; 1996.
17. Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia. Stroke 33:1834-1839.
18. Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38:735-767.
19. Polvikoski T, Sulkava R, Myllykangas L, Notkola IL, Niinistö L, Verkkoniemi, et al. (2001) Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology 56:1690-1696.
20. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ (in press) A randomized, placebo-controlled study of memantine, an uncompetitive NMDA antagonist, in patients with moderate to severe Alzheimer's disease.
21. Rothman SM, Olney JW (1987) Excitotoxicity and the NMDA receptor. Trends Neurosci 10:299-302.
22. Rüther E, Glaser A, Bleich D, Degner D, Wiltfang J (2000) A prospective PMS study to validate the sensitivity for change of the D-Scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychology 33:103-108.
23. Wenk GL, Quack G, Möbius HJ, Danysz W (2000) No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 66:1079-1083.
24. Wilcock G, Möbius HJ, Stöffler A (2002) A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol 17:297-305.
25. Winblad B, Poritis N (1999) Memantine in severe dementia: results of the MBEST study. Int J Geriatr Psychiatry 14:135-146.
26. Wu J, Anwyl R, Rowan MJ (1995) Beta-amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 6:2409-2413.
27. Zurad EG (2001) New treatments of Alzheimer disease: a review. Drug Benefit Trends 13:27-40.